Spinal Surgical Service, Hospital for Special Surgery, Weill Medical College of Cornell University, New York, USA.
Eur Spine J. 2010 Jun;19(6):931-9. doi: 10.1007/s00586-009-1263-7. Epub 2010 Jan 9.
A novel rat model was used to investigate the effect of nitric oxide synthase inhibition in posterior spinal fusion augmented with recombinant human bone morphogenetic protein-2. Nitric oxide (NO) has important physiological functions including the modulation of fracture healing. Recombinant human BMP-2 (rhBMP-2) enhances spinal fusion. It is not known whether nitric oxide has a role in rhBMP-2 enhanced spinal fusion and remodeling. A novel rat intertransverse fusion model was created using a defined volume of bone graft along with a collagen sponge carrier, which was compacted and delivered using a custom jig. The control groups consisted of a sham group (S, n = 20), an autograft + carrier group (A, n = 28) and a group consisting of 43 microg of rhBMP-2 mixed with autograft + carrier (AB, n = 28). Two experimental groups received a nitric oxide synthase (NOS) inhibitor, N (G)-nitro L-arginine methyl ester, in a dose of 1 mg/ml ad lib in the drinking water (AL, n = 28) and one of these experimental groups had rhBMP-2 added to the graft mixture at the time of surgery (ALB, n = 28). Rats were killed at 22 and 44 days, spinal columns subjected to radiology, biomechanics and histology. On a radiographic score (0-4) indicating progressive maturation of bone fusion mass, no difference was found between the A and AL groups, however, there was a significant enhancement of fusion when rhBMP-2 was added when compared to the A group (P < 0.001). However, on day 44, the ALB group showed significantly less fusion progression when compared to the AB group (P < 0.01). There was a 25% (P < 0.05) more fusion-mass-area in day 44 of ALB group when compared to day 44 of the AB group indicating that NOS inhibition delayed the remodeling of the fusion mass. Biomechanically, the rhBMP-2 groups were stiffer at all time points compared to the NOS inhibited groups. Decalcified histology demonstrated that there was a delay in graft incorporation whenever NOS was inhibited (AL and ALB groups) as assessed by a 5 point histological maturation score. In a novel model of rat intertransverse process fusion, nitric oxide synthase modulates rhBMP-2 induced corticocancellous autograft incorporation.
一种新型大鼠模型被用于研究在使用重组人骨形态发生蛋白-2 增强的后路脊柱融合中抑制一氧化氮合酶的效果。一氧化氮(NO)具有重要的生理功能,包括调节骨折愈合。重组人骨形态发生蛋白-2(rhBMP-2)可增强脊柱融合。目前尚不清楚一氧化氮是否在 rhBMP-2 增强的脊柱融合和重塑中起作用。使用定义体积的骨移植物和胶原海绵载体创建了新型大鼠横突间融合模型,该模型使用定制的夹具进行压缩和输送。对照组包括假手术组(S,n = 20)、自体移植物+载体组(A,n = 28)和 43 微克 rhBMP-2 与自体移植物+载体混合组(AB,n = 28)。两个实验组以 1mg/ml 的剂量自由饮用 N(G)-硝基-L-精氨酸甲酯(NOS)抑制剂,其中一个实验组在手术时将 rhBMP-2 添加到移植物混合物中(ALB,n = 28)。22 天和 44 天后处死大鼠,对脊柱进行放射学、生物力学和组织学检查。在表示骨融合质量逐渐成熟的放射学评分(0-4)上,A 组和 AL 组之间没有差异,但是当与 A 组相比添加 rhBMP-2 时,融合明显增强(P <0.001)。然而,在第 44 天,与 AB 组相比,ALB 组的融合进展明显较少(P <0.01)。与 AB 组相比,ALB 组第 44 天的融合质量面积增加了 25%(P <0.05),表明 NOS 抑制延迟了融合质量的重塑。生物力学上,rhBMP-2 组在所有时间点都比 NOS 抑制组更硬。脱钙组织学显示,只要抑制 NOS(AL 和 ALB 组),移植物的掺入就会延迟(通过 5 分组织学成熟评分评估)。在大鼠横突间融合的新型模型中,一氧化氮合酶调节 rhBMP-2 诱导的皮质松质自体移植物的掺入。